Spyre Therapeutics, Inc. (SYRE)
85.69
-1.40
(-1.61%)
USD |
NASDAQ |
Sep 25, 16:00
85.70
+0.02
(+0.02%)
After-Hours: 19:59
Spyre Therapeutics Net Income (TTM) : -168.22M for June 30, 2026
Net Income (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -168.22M |
| March 31, 2026 | -168.74M |
| December 31, 2025 | -135.82M |
| September 30, 2025 | -127.66M |
| June 30, 2025 | -170.19M |
| March 31, 2025 | -160.22M |
| December 31, 2024 | -150.54M |
| September 30, 2024 | 73.86M |
| June 30, 2024 | 87.46M |
| March 31, 2024 | -102.87M |
| December 31, 2023 | -94.88M |
| September 30, 2023 | -294.43M |
| June 30, 2023 | -272.56M |
| March 31, 2023 | -77.80M |
| December 31, 2022 | -83.82M |
| September 30, 2022 | -85.44M |
| June 30, 2022 | -87.51M |
| March 31, 2022 | -72.02M |
| December 31, 2021 | -65.80M |
| September 30, 2021 | -68.07M |
| June 30, 2021 | -65.80M |
| March 31, 2021 | -80.38M |
| Date | Value |
|---|---|
| December 31, 2020 | -80.89M |
| September 30, 2020 | -79.67M |
| June 30, 2020 | -83.21M |
| March 31, 2020 | -79.82M |
| December 31, 2019 | -78.25M |
| September 30, 2019 | -71.66M |
| June 30, 2019 | -62.00M |
| March 31, 2019 | -53.40M |
| December 31, 2018 | -44.35M |
| September 30, 2018 | -35.93M |
| June 30, 2018 | -31.89M |
| March 31, 2018 | -29.11M |
| December 31, 2017 | -27.24M |
| September 30, 2017 | -26.24M |
| June 30, 2017 | -24.60M |
| March 31, 2017 | -23.40M |
| December 31, 2016 | -21.70M |
| September 30, 2016 | -20.20M |
| June 30, 2016 | -17.38M |
| March 31, 2016 | -13.37M |
| December 31, 2015 | -11.30M |
| September 30, 2015 | -10.49M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| AbbVie, Inc. | 6.274B |
| Incyte Corp. | 1.612B |
| SELLAS Life Sciences Group, Inc. | -32.46M |
| Relay Therapeutics, Inc. | -286.04M |
| ACADIA Pharmaceuticals, Inc. | 380.48M |